Drug-drug interaction between prescription and medication statement

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

[a fhir:DetectedIssue;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "ddi"]; # 
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ];
     fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <p><b>Severity: High</b> - Risk of internal bleeding</p>\n      <p>Those who take acetaminophen along with the widely used blood-thinning drug warfarin may face the risk of serious internal bleeding. People on warfarin who take acetaminophen for at least seven days in a row should be closely watched for bleeding.</p>\n      <ul>\n        <li><a href=\"MedicationUsage/tylenol\">500 mg Acetaminophen tablet 1/day, PRN since 2010</a></li>\n        <li><a href=\"MedicationRequest/warfarin\">Warfarin 1 MG TAB prescribed Jan. 5, 2014</a></li>\n      </ul>\n      <p>Mitigation: Jan 5, 2014 by Dr. Adam Careful: </p>\n      <p>Asked patient to discontinue regular use of Tylenol and to consult with clinician if they need to resume to allow appropriate INR monitoring</p>\n    </div>"
  ]; # 
  fhir:DetectedIssue.status [ fhir:value "final"]; # 
  fhir:DetectedIssue.category [
     fhir:index 0;
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/v3-ActCode" ];
       fhir:Coding.code [ fhir:value "DRG" ];
       fhir:Coding.display [ fhir:value "Drug Interaction Alert" ]
     ]
  ]; # 
  fhir:DetectedIssue.code [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/v3-ActCode" ];
       fhir:Coding.code [ fhir:value "DRG" ];
       fhir:Coding.display [ fhir:value "Drug Interaction Alert" ]
     ]
  ]; # 
  fhir:DetectedIssue.severity [ fhir:value "high"]; # 
  fhir:DetectedIssue.subject [
     fhir:Reference.reference [ fhir:value "Device/example" ]
  ]; # 
  fhir:DetectedIssue.identifiedDateTime [ fhir:value "2014-01-05"^^xsd:date]; # 
  fhir:DetectedIssue.implicated [
     fhir:index 0;
     fhir:Reference.reference [ fhir:value "MedicationUsage/example001" ];
     fhir:Reference.display [ fhir:value "500 mg Acetaminophen tablet 1/day, PRN since 2010" ]
  ], [
     fhir:index 1;
     fhir:Reference.reference [ fhir:value "MedicationRequest/medrx0331" ];
     fhir:Reference.display [ fhir:value "Warfarin 1 MG TAB prescribed Jan. 15, 2015" ]
  ]; # 
  fhir:DetectedIssue.detail [ fhir:value "Risk of internal bleeding.  Those who take acetaminophen along with the widely used blood-thinning drug warfarin may face the risk of serious internal bleeding. People on warfarin who take acetaminophen for at least seven days in a row should be closely watched for bleeding."]; # 
  fhir:DetectedIssue.mitigation [
     fhir:index 0;
     fhir:DetectedIssue.mitigation.action [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://terminology.hl7.org/CodeSystem/v3-ActCode" ];
         fhir:Coding.code [ fhir:value "13" ];
         fhir:Coding.display [ fhir:value "Stopped Concurrent Therapy" ]
       ];
       fhir:CodeableConcept.text [ fhir:value "Asked patient to discontinue regular use of Tylenol and to consult with clinician if they need to resume to allow appropriate INR monitoring" ]
     ];
     fhir:DetectedIssue.mitigation.date [ fhir:value "2014-01-05"^^xsd:date ];
     fhir:DetectedIssue.mitigation.author [
       fhir:Reference.reference [ fhir:value "Practitioner/example" ];
       fhir:Reference.display [ fhir:value "Dr. Adam Careful" ]
     ]
  ]] . # 

# - ontology header ------------------------------------------------------------

[a owl:Ontology;
  owl:imports fhir:fhir.ttl] .

# -------------------------------------------------------------------------------------